JW Pharmaceutical Corporation (001065.KS)
KRW 29450.0
(-1.01%)
KRW 29450.0
(-1.01%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 30 Billion KRW | 1522.23% |
| 2022 | 1.84 Billion KRW | -98.49% |
| 2021 | 122.07 Billion KRW | 62.97% |
| 2020 | 74.9 Billion KRW | 136.69% |
| 2019 | 31.64 Billion KRW | -32.94% |
| 2018 | 47.18 Billion KRW | 249.55% |
| 2017 | 13.5 Billion KRW | -72.67% |
| 2016 | 49.4 Billion KRW | -50.87% |
| 2015 | 100.55 Billion KRW | -24.11% |
| 2014 | 132.49 Billion KRW | 151.95% |
| 2013 | 52.58 Billion KRW | -57.66% |
| 2012 | 124.21 Billion KRW | -24.74% |
| 2011 | 165.04 Billion KRW | -7.98% |
| 2010 | 179.36 Billion KRW | 24.93% |
| 2009 | 143.57 Billion KRW | 257.2% |
| 2008 | 40.19 Billion KRW | -26.92% |
| 2007 | 55 Billion KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 30 Billion KRW | 0.0% |
| 2024 Q2 | 30 Billion KRW | 0.0% |
| 2023 Q1 | 29.55 Billion KRW | 1498.2% |
| 2023 Q2 | 54.15 Billion KRW | 83.23% |
| 2023 FY | 30 Billion KRW | 1522.23% |
| 2023 Q3 | 60.16 Billion KRW | 11.1% |
| 2023 Q4 | 30 Billion KRW | -50.14% |
| 2022 Q4 | 1.84 Billion KRW | -96.39% |
| 2022 Q2 | 151.75 Billion KRW | 0.02% |
| 2022 Q3 | 51.2 Billion KRW | -66.26% |
| 2022 Q1 | 151.71 Billion KRW | 24.29% |
| 2022 FY | 1.84 Billion KRW | -98.49% |
| 2021 Q3 | 100.71 Billion KRW | -0.11% |
| 2021 FY | 122.07 Billion KRW | 62.97% |
| 2021 Q1 | 50.54 Billion KRW | -32.52% |
| 2021 Q4 | 122.07 Billion KRW | 21.2% |
| 2021 Q2 | 100.82 Billion KRW | 99.48% |
| 2020 Q2 | 57.28 Billion KRW | 14.32% |
| 2020 Q1 | 50.11 Billion KRW | 58.35% |
| 2020 Q3 | 46.02 Billion KRW | -19.65% |
| 2020 Q4 | 74.9 Billion KRW | 62.74% |
| 2020 FY | 74.9 Billion KRW | 136.69% |
| 2019 Q2 | 26.14 Billion KRW | -5.57% |
| 2019 Q1 | 27.69 Billion KRW | -41.32% |
| 2019 FY | 31.64 Billion KRW | -32.94% |
| 2019 Q3 | 34.61 Billion KRW | 32.38% |
| 2019 Q4 | 31.64 Billion KRW | -8.58% |
| 2018 Q3 | 28.74 Billion KRW | -4.82% |
| 2018 Q2 | 30.19 Billion KRW | -4.6% |
| 2018 Q1 | 31.65 Billion KRW | 134.49% |
| 2018 FY | 47.18 Billion KRW | 249.55% |
| 2018 Q4 | 47.18 Billion KRW | 64.17% |
| 2017 Q3 | 34.98 Billion KRW | -4.1% |
| 2017 Q2 | 36.48 Billion KRW | -3.94% |
| 2017 Q1 | 37.97 Billion KRW | -23.13% |
| 2017 Q4 | 13.5 Billion KRW | -61.41% |
| 2017 FY | 13.5 Billion KRW | -72.67% |
| 2016 FY | 49.4 Billion KRW | -50.87% |
| 2016 Q1 | 68.92 Billion KRW | -31.45% |
| 2016 Q2 | 52.38 Billion KRW | -24.0% |
| 2016 Q3 | 98.96 Billion KRW | 88.93% |
| 2016 Q4 | 49.4 Billion KRW | -50.08% |
| 2015 Q2 | 83.77 Billion KRW | -28.99% |
| 2015 Q1 | 117.97 Billion KRW | -10.96% |
| 2015 Q4 | 100.55 Billion KRW | 22.41% |
| 2015 Q3 | 82.14 Billion KRW | -1.94% |
| 2015 FY | 100.55 Billion KRW | -24.11% |
| 2014 Q2 | 129.73 Billion KRW | 51.45% |
| 2014 Q1 | 85.66 Billion KRW | 62.89% |
| 2014 Q3 | 130.92 Billion KRW | 0.92% |
| 2014 Q4 | 132.49 Billion KRW | 1.2% |
| 2014 FY | 132.49 Billion KRW | 151.95% |
| 2013 FY | 52.58 Billion KRW | -57.66% |
| 2013 Q4 | 52.58 Billion KRW | -30.77% |
| 2013 Q3 | 75.96 Billion KRW | -9.88% |
| 2013 Q2 | 84.29 Billion KRW | -2.68% |
| 2013 Q1 | 86.61 Billion KRW | -30.27% |
| 2012 Q1 | 205.61 Billion KRW | 0.0% |
| 2012 FY | 124.21 Billion KRW | -24.74% |
| 2012 Q4 | 124.21 Billion KRW | 0.0% |
| 2011 FY | 165.04 Billion KRW | -7.98% |
| 2011 Q3 | 147.49 Billion KRW | -21.31% |
| 2011 Q1 | 205.7 Billion KRW | 14.69% |
| 2011 Q2 | 187.43 Billion KRW | -8.88% |
| 2010 Q1 | 149.24 Billion KRW | 3.95% |
| 2010 Q2 | 164.36 Billion KRW | 10.13% |
| 2010 FY | 179.36 Billion KRW | 24.93% |
| 2010 Q4 | 179.36 Billion KRW | 19.58% |
| 2010 Q3 | 149.98 Billion KRW | -8.75% |
| 2009 Q1 | 57.82 Billion KRW | 43.85% |
| 2009 Q4 | 143.57 Billion KRW | 1.96% |
| 2009 Q3 | 140.81 Billion KRW | 40.51% |
| 2009 FY | 143.57 Billion KRW | 257.2% |
| 2009 Q2 | 100.21 Billion KRW | 73.32% |
| 2008 FY | 40.19 Billion KRW | -26.92% |
| 2008 Q4 | 40.19 Billion KRW | 3.72% |
| 2008 Q3 | 38.75 Billion KRW | 10.73% |
| 2008 Q2 | 35 Billion KRW | -36.36% |
| 2008 Q1 | 55 Billion KRW | 0.0% |
| 2007 Q4 | 55 Billion KRW | 37.5% |
| 2007 FY | 55 Billion KRW | 0.0% |
| 2007 Q2 | 60 Billion KRW | 0.0% |
| 2007 Q1 | 60 Billion KRW | 0.0% |
| 2007 Q3 | 40 Billion KRW | -33.33% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -119.941% |
| Dong-A Socio Holdings Co., Ltd. | 202.06 Billion KRW | 85.153% |
| Ildong Holdings Co., Ltd. | 29.87 Billion KRW | -0.413% |
| HANDOK Inc. | 123.78 Billion KRW | 75.764% |
| Kukje Pharma Co., Ltd. | 475.74 Million KRW | -6205.928% |
| Yuhan Corporation | 60.23 Billion KRW | 50.194% |
| Dong-A ST Co., Ltd. | 161.99 Billion KRW | 81.481% |
| SAMSUNG PHARM. Co., LTD. | 101.81 Million KRW | -29364.399% |
| Hanmi Pharm. Co., Ltd. | 82.02 Billion KRW | 63.427% |
| Hanall Biopharma Co.,Ltd | 590.3 Million KRW | -4982.082% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -395.868% |
| Dong Sung Bio Pharm.Co.,Ltd. | 18.52 Billion KRW | -61.966% |
| MYUNGMOON Pharm co.,Ltd | 12.58 Billion KRW | -138.394% |
| Hana Pharm Co., Ltd. | 1.59 Billion KRW | -1776.353% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -119.941% |
| Ilsung Pharmaceuticals Co., Ltd. | 119.67 Million KRW | -24967.18% |
| REYON Pharmaceutical Co., Ltd. | 121 Billion KRW | 75.207% |
| Aprogen pharmaceuticals,Inc. | 32 Billion KRW | 6.25% |
| JW Holdings Corporation | 20.65 Billion KRW | -45.227% |
| Ildong Pharmaceutical Co., Ltd. | 14.82 Billion KRW | -102.358% |
| Chong Kun Dang Pharmaceutical Corp. | 30 Billion KRW | 0.0% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -13601.07% |
| Hyundai Pharmaceutical Co., Ltd. | 580.64 Million KRW | -5066.658% |
| Samil Pharmaceutical Co.,Ltd | 49.56 Billion KRW | 39.478% |
| Jeil Pharmaceutical Co.,Ltd | 4.45 Billion KRW | -573.854% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -119.941% |
| Kwang Dong Pharmaceutical Co., Ltd. | 19.02 Billion KRW | -57.665% |
| Daewoong pharmaceutical Co.,Ltd | 93.41 Billion KRW | 67.885% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 0.0% |
| Yuhan Corporation | 60.23 Billion KRW | 50.194% |
| Jeil Pharma Holdings Inc | 10.5 Billion KRW | -185.714% |
| Yungjin Pharm. Co., Ltd. | 40.37 Billion KRW | 25.702% |
| Suheung Co., Ltd. | 74 Billion KRW | 59.463% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 0.0% |
| Samjin Pharmaceuticals Co., Ltd. | 4.16 Billion KRW | -620.005% |
| Korea United Pharm Inc. | 10.96 Billion KRW | -173.66% |
| CKD Bio Corp. | 69.43 Billion KRW | 56.792% |
| Daewon Pharmaceutical Co., Ltd. | 34.57 Billion KRW | 13.232% |
| Dongwha Pharm.Co.,Ltd | 16.12 Billion KRW | -86.016% |
| Whan In Pharm Co.,Ltd. | 307.05 Million KRW | -9670.198% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -13601.07% |
| Chong Kun Dang Holdings Corp. | 72.11 Billion KRW | 58.398% |
| Boryung Corporation | 151.7 Billion KRW | 80.225% |
| Bukwang Pharmaceutical Co., Ltd. | 78.52 Billion KRW | 61.796% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -395.868% |
| JW Lifescience Corporation | 168 Million KRW | -17757.143% |